Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Almorexant in Primary Insomnia

This study has been completed.
Sponsor:
Information provided by:
Actelion
ClinicalTrials.gov Identifier:
NCT00640848
First received: March 18, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
  Purpose

The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.


Condition Intervention Phase
Insomnia
Primary Insomnia
Drug: almorexant
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multi-Center, Multiple-Stage, Double-Blind, Randomized, Placebo-Controlled, Two-Way Crossover, Single-Dose Study to Investigate the Effects of ACT-078573 on Sleep Measured by Polysomnography in Patients With Primary Insomnia

Further study details as provided by Actelion:

Primary Outcome Measures:
  • Sleep efficiency (%) assessed by PSG (polysomnography) [ Time Frame: Between 10pm-12am (=lights out) until 480 minutes thereafter (=lights on) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • LPS (Latency to Persistent Sleep) [min] assessed by PSG (polysomnography) [ Time Frame: Time from start of recording to the beginning of the first continuous 20 epochs of non-wake ] [ Designated as safety issue: No ]

Enrollment: 161
Study Start Date: May 2006
Study Completion Date: September 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: almorexant
1 dose of 400 mg in two treatment sequences
Other Name: ACT-078573
Experimental: 2 Drug: almorexant
1 dose of 200 mg in two treatment sequences
Other Name: ACT-078573
Experimental: 3 Drug: almorexant
1 dose of 100 mg in two treatment sequences
Other Name: ACT-078573
Experimental: 4 Drug: almorexant
1 dose of 50 mg mg in two treatment sequences
Other Name: ACT-078573
Experimental: 5 Drug: almorexant
1 dose of 1000 mg in two treatment sequences
Other Name: ACT-078573

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women 18 - 65 years of age (inclusive).
  • Women of childbearing potential must have a negative urine pregnancy test at the screening visit, the screening adaptation night, and pre-treatment and use a reliable method of contraception during the entire study duration and for at least 3 months after study drug intake.

Reliable methods of contraception are:

  • Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.
  • Intra-uterine devices.
  • Oral, injectable, implantable or transdermal contraceptives only in combination with a barrier method.

    • Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.

Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.

  • Body mass index (BMI) between 18 and 30 kg/m2 (limits included) at screening visit.
  • 12-lead ECG without clinically relevant abnormalities at screening visit.
  • Hematology and biochemistry test results not deviating from the normal range to a clinically relevant extent at screening visit and following the screening/adaptation night.
  • Primary insomnia by DSM-IV-TR criteria based on medical history and the assessments performed at screening visit.
  • History of the following for at least 3 months prior to the screening visit:

    • Usual reported subjective total sleep time (TST) 3 - 6 hours.
    • Usual sleep disturbance with a subjective sleep onset latency of > 30 min.
    • Daytime complaints associated with poor sleep (e.g., fatigue, irritability, difficulty concentrating).
  • Polysomnography (PSG) at screening/adaptation night confirming TST < 6 h and LPS ≥ 20 min.
  • Willingness to refrain from CNS-active drugs for 5 half-lives of the respective drug (but at least 1 week) prior to the screening/adaptation night and up to the end of treatment period 2. The usage of short-acting hypnotics (defined as hypnotics with a half-life of up to and including 10 hours) is allowed up to 48 hours prior to each PSG night, i.e., prior to the screening/adaptation night and prior to the treatment PSG nights.
  • Urine drug test negative for barbiturates, cannabinoids, amphetamines, and cocaine at screening visit 1, screening/adaptation PSG night and pre-treatment. Urine drug test negative for benzodiazepines and opiates at screening/adaptation PSG night and pre-treatment.
  • Signed informed consent prior to any study-mandated procedure.

Exclusion Criteria:

  • Symptom assessment questionnaire (SBB) for diagnosis of apnea resulting in a score > 2 at screening visit.
  • Zung self-rating depression scale (SDS) and/or Zung self-rating anxiety scale (SAS) resulting in a raw score ≥ 50 at screening visit.
  • Restless legs syndrome and/or meeting all four essential diagnostic criteria for RLS (see Appendix 10).
  • Insomnia due to sleep apnea or periodic limb movement disorder as assessed by PSG at screening/adaptation night:

    • apnea/hypopnea index (AHI) > 10/h
    • periodic limb movement arousal index > 10/h
  • Major depressive disorder, severe psychosis, or significant anxiety disorder.
  • Pregnancy or breast-feeding.
  • Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg at screening visit.
  • Within the 2-month period prior to the screening visit, clinical evidence of alcoholism or drug abuse.
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease or a disease which may affect the pharmacokinetics of the study drug.
  • Treatment with strong inhibitors of CYP3A4 (e.g., azole derivatives, ritonavir, clarithromycin) within 1 week prior to the screening/adaptation PSG night and up to the end of treatment period 2.
  • Excessive caffeine consumption (regular caffeine consumption of > 7 units per day).
  • Night shift workers.
  • Known hypersensitivity to any excipients of the drug formulation.
  • Planned treatment or treatment with another investigational drug within 1 month prior to randomization and up to the end of treatment period 2.
  • Known concomitant life-threatening disease with a life expectancy < 24 months.
  • Unstable medical abnormality, significant medical disorder or acute illness.
  • Recruitment of the same patient twice to the same dose level. Patients may be recruited to a lower dose level, provided that there are at least 28 days between last study drug administration and screening/adaptation PSG night.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00640848

Locations
Austria
Medical University of Innsbruck, Dept. of Neurology Sleep Disorder Unit
Innsbruck, Austria
The Siesta Group
Vienna, Austria
Medical University of Vienna, Clinic of Neurology
Vienna, Austria
Medical University of Vienna, University Clinic of Psychiatrie
Vienna, Austria
Denmark
Scan Sleep
Copenhagen, Denmark
Glostrup University Hospital Department of Sleep Medicine
Glostrup, Denmark
Finland
Skogby Sleep Clinic
Espoo, Finland
Sleep Research Unit, Dentalia, University of Turku
Turku, Finland
Germany
Charite Campus Benjamin Franklin, Klinik und Hochschulambulanz fur Psychiatrie and Psychotherapie
Berlin, Germany
Department of Internal Medicine, Center for Sleep Medicine
Berlin, Germany
St Hedwig-Krankenhaus, Akademisches Lehrkrankenhaus der Charite
Berlin, Germany
Department of Psychiatry and Psychotherapy of the University Hospital of Freiburg
Freiburg, Germany
St. Valentinushaus Klinik fur Psychiatrie und Psychotherapie
Kiedrich, Germany
Universitatsklinikum Giessen und Marburg, Standort Marburg, Nervenklinik
Marburg, Germany
Klinik und Poliklinik fur Psychiatrie, Psychosomatik und Psychotherapie der Universitat am Bezirsklinikum
Regensburg, Germany
SOMNIBENE Institut fur Medzinische Forschung und Schlafmedizin
Schwerin, Germany
Israel
Technion Sleep Medicine Center, Rambam Medical Center
Haifa, Israel
Assuta Medical Centers
Petah Tikva, Israel
Netherlands
Medisch Centrum Haaglanden-Westeinde Ziekenhuis, Slaapcentrum (Holland Sleep Research)
Den Haag, Netherlands
Spain
Hospital de la Ribera
Alzira, Spain
Hospital de la Santa Crue/Sant Pau, Institut de Recerca
Barcelona, Spain
Sweden
Skaraborg Hospital, Sleep Medicine Unit, Department of Neurorehabilitation
Skoevde, Sweden
Uppsala Akademiska Hospital, Sleep Disorder Unit
Uppsala, Sweden
Switzerland
Psychiatric University Clinics (UPK) Basel, Dept. for Depression Research, Sleep Medicine and Neurophysiology
Basel, Switzerland
University Hospital Zurich (USZ), Neurology Polyclinic, Center for Sleep Medicine
Zurich, Switzerland
United Kingdom
The Edinburgh Sleep Centre
Edinburgh, United Kingdom
Medical Director, The London Sleep Centre
London, United Kingdom
Sponsors and Collaborators
Actelion
Investigators
Study Director: Jasper Dingemanse, PhD Actelion
Study Director: Eleornora Chiossi, MSc Actelion
Study Director: Petra Hoever, MSc Actelion
Study Director: Fabrice Kramer, MD Actelion
Principal Investigator: Georg Dorffner, Prof. Dr. The Siesta Group
  More Information

No publications provided by Actelion

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jasper Dingemanse, Actelion
ClinicalTrials.gov Identifier: NCT00640848     History of Changes
Other Study ID Numbers: AC-057-103
Study First Received: March 18, 2008
Last Updated: March 18, 2008
Health Authority: Austria: Federal Office for Safety in Health Care
Denmark: Danish Medicines Agency
Finland: Finnish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Israel: Ethics Commission
Israel: Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Dyssomnias
Mental Disorders
Nervous System Diseases
Sleep Disorders
Sleep Disorders, Intrinsic

ClinicalTrials.gov processed this record on November 23, 2014